RemeGen Co. Ltd (REGMF PINK) stock market data APIs
$11.0429
-1.16(-10.5%)
as of May 6, 2026
Try our APIs with
free plan!
RemeGen Co. Ltd Financial Data Overview
Price chart is built with
Anychart
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Prev. Close
11.0429
Open
9.8792
High
11.0446
Low
9.7876
52 wk Range
5.06-12.525
Market Cap
6 171 M
P/E Ratio
57.6268
Shares Outstanding
209 M
Revenue
3 381 M
EPS
0.0847
Beta
0.476
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get RemeGen Co. Ltd data using free add-ons & libraries
Get RemeGen Co. Ltd Fundamental Data
RemeGen Co. Ltd Fundamental data includes:
- Net Revenue: 3 381 M
- EBITDA: 599 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RemeGen Co. Ltd News
New
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
DelveInsight Business Research LLP The generalized myasthenia gravis treatment pipeline features several promising late-stage candidates, including IMVT-1402 (Immunovant/Roivant Sciences), Descartes-...
3 Asian Growth Companies With High Insider Ownership Growing Revenues Up To 24%
In the current landscape, Asian markets are navigating through challenges posed by energy price volatility and geopolitical tensions, which have influenced investor sentiment and economic forecasts. A...
Vertex Pops On 'Remarkable' Results For Chronic Kidney Disease Drug
Vertex stock popped late Monday on promising test results for a drug that could treat a chronic autoimmune disease that destroys the kidneys. Continue Reading
Asian Market Picks: Mao Geping Cosmetics And 2 Other Stocks That May Be Priced Below Their Estimated Value
As global markets navigate a period of volatility, with technology stocks experiencing setbacks and value-oriented sectors gaining traction, investors are increasingly turning their attention to the A...
Get RemeGen Co. Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
